NO992187L - Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav - Google Patents

Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav

Info

Publication number
NO992187L
NO992187L NO992187A NO992187A NO992187L NO 992187 L NO992187 L NO 992187L NO 992187 A NO992187 A NO 992187A NO 992187 A NO992187 A NO 992187A NO 992187 L NO992187 L NO 992187L
Authority
NO
Norway
Prior art keywords
enzyme
tnf
methods
trre
compositions
Prior art date
Application number
NO992187A
Other languages
English (en)
Other versions
NO992187D0 (no
Inventor
Gale A Granger
Tetsuya Gatanaga
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO992187D0 publication Critical patent/NO992187D0/no
Publication of NO992187L publication Critical patent/NO992187L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
NO992187A 1996-11-06 1999-05-05 Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav NO992187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3076196P 1996-11-06 1996-11-06
PCT/US1997/019930 WO1998020140A1 (en) 1996-11-06 1997-11-05 Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof

Publications (2)

Publication Number Publication Date
NO992187D0 NO992187D0 (no) 1999-05-05
NO992187L true NO992187L (no) 1999-07-01

Family

ID=21855891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992187A NO992187L (no) 1996-11-06 1999-05-05 Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav

Country Status (14)

Country Link
US (3) US6569664B1 (no)
EP (1) EP0938548B1 (no)
JP (1) JP2001508648A (no)
KR (1) KR100533531B1 (no)
AT (1) ATE403714T1 (no)
AU (1) AU744873B2 (no)
BR (1) BR9712900A (no)
CA (1) CA2270898A1 (no)
DE (1) DE69738887D1 (no)
ID (1) ID22049A (no)
IL (1) IL129787A0 (no)
NO (1) NO992187L (no)
NZ (1) NZ335864A (no)
WO (1) WO1998020140A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335864A (en) * 1996-11-06 2001-09-28 Univ California Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
EP1067962B1 (en) * 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
EP1263788A2 (en) * 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2001064856A2 (en) * 2000-02-28 2001-09-07 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
JP5271480B2 (ja) * 2003-04-30 2013-08-21 味の素株式会社 体温低下抑制剤
EP1699478A2 (en) * 2003-09-23 2006-09-13 Meyer Pharmaceuticals, LLC Treating inflammation using a biological agent that causes cells to release cytokine receptors
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
TWI498137B (zh) * 2006-06-30 2015-09-01 Abbvie Biotechnology Ltd 自動注射裝置
US9002096B2 (en) 2009-01-06 2015-04-07 Siemens Healthcare Diagnostics Inc. Method and apparatus for determining a liquid level in a container using imaging
RU2602039C2 (ru) 2011-01-24 2016-11-10 Эббви Байотекнолоджи Лтд. Автоматические инъекционные устройства, имеющие наформованные поверхности захвата

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5643740A (en) 1983-02-24 1997-07-01 Ronald J. Billing Monoclonal antibody specific for activated lymphocytes and monocytes
US5001061A (en) * 1983-06-22 1991-03-19 Lubrizol Genetics, Inc. nifD promoter of Bradyrhizobium
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
WO1986002271A1 (en) 1984-10-19 1986-04-24 Chiron Corporation Promotion of wound healing with human epidermal growth factor prepared from recombinant dna
ATE89005T1 (de) 1985-02-05 1993-05-15 Synergen Biolog Inc Rekombinantes vektorsystem fuer metalloproteinase- inhibitorsequenz und dessen verwendung und herstellung nach dem rekombinant-dns-verfahren.
US4695590A (en) 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US6869924B1 (en) 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
ATE219776T1 (de) 1989-03-21 2002-07-15 Us Secretary United States Dep Matrizenmetalloproteinase-inhibitor-peptide
US5140043A (en) 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5270326A (en) 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
JP3068879B2 (ja) 1991-03-09 2000-07-24 フマキラー株式会社 精製ダニアレルゲン
EP0534907B1 (en) 1991-09-26 1998-08-05 Nippon Zoki Pharmaceutical Co., Ltd. The use of furanone derivatives for the prevention or treatment of autoimmune diseases
JP3512795B2 (ja) 1991-09-30 2004-03-31 アメリカ合衆国 組換免疫毒素
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
CA2160139A1 (en) 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
WO1995009913A1 (en) 1993-10-07 1995-04-13 Incyte Pharmaceuticals, Inc. Human monocyte/macrophage derived metalloproteinase inhibitor
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
EP0693556B1 (en) * 1994-01-28 2004-10-06 Ajinomoto Co., Inc. Transglutaminase originating in japanese oyster
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
ZA955430B (en) 1994-07-07 1997-02-13 Res Dev Foundation Tumor necrosis factor receptor-ii associated protein kinase and method for their use
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6090605A (en) 1996-03-11 2000-07-18 The Board Of Trustees Of The University Of Arkansas Purified porcine kidney L-fucose kinase
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
US5834236A (en) 1996-06-27 1998-11-10 The Salk Institute For Biological Studies AATT repeat transcription enhancer element
US5853977A (en) * 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
NZ335864A (en) * 1996-11-06 2001-09-28 Univ California Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
AU726374B2 (en) 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
US6183997B1 (en) 1997-03-21 2001-02-06 Stratagene Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same

Also Published As

Publication number Publication date
IL129787A0 (en) 2000-02-29
JP2001508648A (ja) 2001-07-03
EP0938548B1 (en) 2008-08-06
US6569664B1 (en) 2003-05-27
NZ335864A (en) 2001-09-28
AU744873B2 (en) 2002-03-07
ID22049A (id) 1999-08-26
CA2270898A1 (en) 1998-05-14
EP0938548A1 (en) 1999-09-01
US6858402B2 (en) 2005-02-22
US20030170776A1 (en) 2003-09-11
US6573062B1 (en) 2003-06-03
KR100533531B1 (ko) 2005-12-06
BR9712900A (pt) 2000-11-28
DE69738887D1 (de) 2008-09-18
AU5162198A (en) 1998-05-29
NO992187D0 (no) 1999-05-05
ATE403714T1 (de) 2008-08-15
KR20000053073A (ko) 2000-08-25
WO1998020140A1 (en) 1998-05-14

Similar Documents

Publication Publication Date Title
NO992187D0 (no) Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav
Sulli et al. Melatonin serum levels in rheumatoid arthritis
Liao et al. Advanced oxidation protein products increase TNF-α and IL-1β expression in chondrocytes via NADPH oxidase 4 and accelerate cartilage degeneration in osteoarthritis progression
Roodman Pathogenesis of myeloma bone disease
Boros et al. Fermented wheat germ extract (Avemar) in the treatment of cancer and autoimmune diseases
Kane et al. The role of corticotropin‐releasing hormone in immune‐mediated cutaneous inflammatory disease
Loeser Aging and osteoarthritis
Norooznezhad et al. Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation
Scott et al. An anti-tumor necrosis factor-α antibody inhibits the development of experimental skin tumors
Xu et al. IL-12p40 impairs mesenchymal stem cell-mediated bone regeneration via CD4+ T cells
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
Schwartz et al. 1, 25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
Chen et al. Licochalcone A inhibits MMPs and ADAMTSs via the NF-κB and Wnt/β-catenin signaling pathways in rat chondrocytes
DE69731540D1 (de) Behandlung von diarrhoe
Corrado et al. Bone effects of biologic drugs in rheumatoid arthritis
Sharwani et al. Photodynamic therapy down-regulates the invasion promoting factors in human oral cancer
Macfarlane et al. Endogenous glucocorticoids during skeletal ageing
Merighi et al. Deregulation of adenosine receptors in psoriatic epidermis: an option for therapeutic treatment
Gamradt et al. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
Atkins et al. Elevated AREG/EGF ratio prior to transplantation is associated with pre-transplant clostridium difficile infection, unresolved tissue damage, and poorer overall survival
Elmazoglu et al. AB0107 S-ALLYL-L-CYSTEINE ATTENUATES INFLAMMATION RELATED OXIDATIVE STRESS PARAMETERS AND INCREASES ADHESION CAPACITY OF PRIMARY HUMAN OSTEOARTHRITIC ARTICULAR CHONDROCYTES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application